Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumour Activity of AK127 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumours
This is an Early Phase 1a/1b dose-escalation and dose-expansion study with one experimental arm. In the dose escalation phase, participants will receive AK127 using the 3+3+3 model given with a fixed regimen of AK104. Both AK127 and AK104 will be administered via intravenous infusion. The dose expansion phase will open at the discretion of the Sponsor.